: Comparative analysis of length of stay, hospitalization costs, opioid use, and discharge status among spine surgery patients with postoperative pain management including intravenous versus oral acetaminophen, Current Medical Research and Opinion, ABSTRACT Background: Recovery from spine surgery is oriented toward restoring functional health outcomes while reducing resource use. Optimal pain management is a key to reaching these objectives. We compared outcomes of spine surgery patients who received standard pain management including intravenous (IV) acetaminophen (APAP) vs. oral APAP. Methods: We performed a retrospective analysis of the Premier database (January 2012 to September 2015) comparing spine surgery patients who received pain management with IV APAP to those who received oral APAP, with no exclusions based on additional pain management. We performed multivariable logistic regression for the discharge and all cause 30-day readmission to the same hospital outcomes and instrumental variable regressions using the quarterly rate of IV APAP use for all hospitalizations by hospital as the instrument in two-stage least squares regressions for length of stay (LOS), hospitalization costs, and average daily morphine equivalent dose (MED) outcomes. Models adjusted for age, gender, race, admission type, 3M All Patient Refined Diagnosis Related Group severity of illness and risk of mortality, hospital size, and indicators for whether the hospital was an academic center and whether it was urban or rural. Results: We identified 112,586 spine surgery patients with 51,835 (46%) having received IV APAP. Subjects averaged 57 and 59 years of age respectively in the IV APAP and oral APAP cohorts and were predominantly non-Hispanic Caucasians and female. In our adjusted models, IV APAP was associated with 0.68 days shorter LOS (95% CI: À0.76 to À0.59, p < .0001), $1175 lower hospitalization costs (95% CI: À$1611 to À$739, p < .0001), 13 mg lower average daily MED (95% CI: À14 mg to À12 mg, p < .0001), 34% lower risk of discharge to a skilled nursing facility (95% CI: 0.63 to 0.69, p < .0001), and 13% less risk of 30-day readmission (95% CI: 0.73 to 1.03). Conclusions: Compared to oral APAP, managing post-spine-surgery pain with IV APAP is associated with less resource use, lower costs, lower doses of opioids, and improved discharge status.
Introduction
The Institute for Healthcare Improvement (IHI) Triple Aim demands simultaneous pursuit of (1) improving the patient care experience, (2) advancing population health, and (3) reducing healthcare costs 1, 2 . Applying this pursuit to postoperative care, recovery from spine surgery is oriented toward restoring functional health outcomes while reducing hospital length of stay (LOS) and medical expenditures. Optimal pain management in this population is a key to reaching these objectives, in addition to reducing the potential for chronic use of opioids 3 . The use of long-acting opioids for post-surgical pain has been demonstrated to be associated with increased health care utilization and costs 4 .
Prior research in multiple surgical areas including orthopedics, obstetrics, and general surgery suggests that multimodal pain management including IV acetaminophen (IV APAP) for acute post-surgical pain improves patient outcomes and reduces hospital resource use [5] [6] [7] [8] [9] . Acetaminophen is a common component of multimodal pain management that may include both pharmaceutical and medical treatments. A recent review of multimodal pain management approaches in spine surgery suggests that APAP has the highest level of available evidence supporting its use 3 . Furthermore, a randomized placebo controlled trial has documented the ability of IV APAP to reduce pain scores after spine surgery 10 .
IV APAP may have some potential advantages over oral administration such as increased APAP concentrations in the cerebrospinal fluid and the ability to administer the medication to patients who are nauseous or unable to utilize oral medications 11 . In addition, concomitant use of oral APAP and opioids commonly used for post-surgical pain may result in inadequate pain control and lead to potential health safety risks due to gastric accumulation of APAP 12 is a paucity of evidence on the comparative effectiveness of the route of administration of APAP in this population. We compared outcomes of spine surgery patients who received usual care pain management including either IV APAP or oral APAP.
Patients and methods
We performed a retrospective cohort study using data from the Premier Database between 1 January 2012 and 30 September 2015, expanding upon methods from a previously published study 5 . This database contains inpatient hospitalization and service records from member hospitals across the US. We used medical-record-level details of International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes, Current Procedural Terminology (CPT) medical procedure codes, and associated cost variables for this study.
We included all patients in the Premier Database with an ICD-9-CM procedure code for spine surgery (03.09, 03.4, 03.53, 03.59, 80.51, 81.02, 81.03, 81.05, 81.06, 81.07, 81.08, 81.32, 81.37, 81.62, 81.63, 84.51) that received either IV or oral APAP beginning on the day of surgery and continuing up to the third postoperative day. The administration of IV and oral APAP was identified from service records indicating a bill for one of the medications. Patients were separated into mutually exclusive groups based on their receipt of IV or oral APAP. Patients who received both IV and oral APAP during the first three postoperative days were not included in the analysis. No other exclusions were made, and all other pain management medications were allowed in both groups.
Outcomes
We pre-specified eight distinct outcomes of interest for this study and compared each between the two groups of spine surgery patients: (1) LOS for the hospitalization, (2) total cost of hospitalization, (3) mean dose of opioids billed; (4-6) opioid related complication rates: (4) nausea/vomiting, (5) respiratory depression (stratified by diagnosis, administration of naloxone, and mechanical ventilation), (6) constipation/ bowel obstruction (including ileus), (7) 30-day readmission to the same hospital, and 8) rate of discharge to skilled nursing care. Length of stay, total hospitalization costs, 30 day readmissions, and discharge status were captured from the hospitalization summary files. The mean morphine equivalent dose (MED) per day was calculated in milligrams starting on the day of admission using an algorithm from the Centers for Disease Control and Prevention 13 . The three opioid related complications were identified utilizing ICD-9-CM diagnosis codes, with naloxone and mechanical ventilation service codes augmenting the respiratory depression diagnosis.
Statistical analyses
We descriptively compared the IV APAP recipients to the oral APAP recipients in terms of age, gender, race, All Patient Refined Diagnosis Related Groups Severity of Illness (APR-DRG SOI), APR-DRG Risk of Mortality (ROM), and the census region of the hospital. We used the chi-square test (for categorical variables) and Student's t-test (for continuous variables) to determine whether differences were significant across the exposure categories. Differences in each outcome were first compared descriptively using Student's t-test for continuous outcomes and unadjusted logistic regression for binary outcomes. We also calculated the proportion of patients within each group who received other analgesics by route and medication type from the day of surgery through discharge by counting the number of patients who received each analgesic and dividing by the total cohort size. Additionally, we subcategorized total costs by hospital department and performed multivariable logistic regressions for each binary outcome (complications, 30 day readmission, and discharge status) adjusting for all available patient demographics and hospital characteristics.
We also attempted to more closely replicate a nonobservational study through an exogenous factor (instrument) by estimating each hospital's rate of IV APAP use for all admissions on a quarterly basis. We constructed separate adjusted two-stage least squares instrumental variable regression models for LOS, total hospitalization cost, and opioid dose. Use of IV APAP (yes/no) was the main independent variable, instrumented by the time-varying quarterly rate of use of IV APAP. Patient demographics, year of admission, and hospital characteristics (bed size, rural/urban indicator, and teaching institution indicator) were included in both stages of the instrumental variable regressions.
This study was approved by the Human Subjects Division at the University of Washington by self-determination by the Principal Investigator. All analyses were conducted using SAS for Windows, Version 9.3 (SAS Institute Inc., Cary, NC, USA) and STATA 13 (StataCorp LP, College Station, TX, USA).
Results
We identified 112,586 spine surgery patients who received APAP, of whom 51,835 (46%) had received IV APAP ( Figure 1 ). Subjects averaged 57 and 59 years of age respectively in the IV APAP and oral APAP cohorts and were predominantly non-Hispanic Caucasians (>70% in both cohorts) and female (52% and 55%, respectively in the IV APAP and oral APAP cohorts). The majority of subjects ranked in the minor or moderate categories for the APR-DRG SOI and ROM (Table 1) . Nearly 80% of the IV APAP cohort received IV APAP on the day of surgery, but only 16% received IV APAP on the first postoperative day. The use of IV APAP continued declining in the following two postoperative days. However, only 20% of the oral APAP cohort used oral APAP on the day of surgery, with 33% receiving oral APAP on the first postoperative day and 27% on the second postoperative day. The most common other analgesic for both groups was IV fentanyl followed by IV hydromorphone. But the use of oral analgesics varied between the groups, with more oral hydrocodone use in the IV APAP cohort and more oral oxycodone use in the PO APAP cohort (Table 2 ). 
Length of stay
The mean unadjusted LOS for IV APAP patients was 3.2 days (SD 3.8) compared to 4.9 days (SD 6.5) with oral APAP, a statistically significant difference of À1.6 days (p < .0001) ( Table 3 ). The instrumental variable regression estimated that IV APAP was associated with 0.68 days shorter hospitalization (95% CI: À0.76 to À0.59, p < .0001) ( Table 4 ).
Hospital costs
Average unadjusted hospitalization costs were $24,800 (SD $20,713) for IV APAP patients and $29,366 (SD $28,817) for oral APAP patients, also significantly lower by $4566 (p < .0001) ( Table 3) . At the department level, IV APAP recipients had higher specialist (p < .0001) and anesthesia costs, but oral APAP recipients had higher surgery, room and board, pharmacy, diagnostic imaging, physical medicine and rehabilitation, laboratory, blood bank, respiratory, IV therapy, and other costs (all p < .0001), with the largest unadjusted differences observed in room and board ($2409) and surgery ($945) ( Figure 2 ). The instrumental variable regression estimated that IV APAP was associated with $1175 lower hospitalization costs (95% CI: À$1611 to À$739, p < .0001) ( Table 4 ).
Opioid consumption
The average opioid MED for IV APAP patients was 43.1 mg (SD 55.2) and 50.8 mg (SD 66.6) for oral APAP patients, an unadjusted difference of À7.7 mg (p < .0001) ( Table 3) . Our instrumental variable regression estimated that IV APAP was associated with 13 mg lower average daily MED (95% CI: À14 mg to À12 mg, p < .0001) ( Table 4 ).
Potential opioid related complications
Complication rates of bowel obstruction (odds ratio 0.72, 95% CI 0.69 to 0.76), nausea and vomiting (odds ratio 0.73, 95% CI: 0.68 to 0.79), and respiratory depression (odds ratio 0.55, 95% CI: 0.53 to 0.58), were estimated to be significantly lower for IV APAP recipients in unadjusted analyses (all p < .0001) ( Table 3) , which held in multivariable logistic regressions ( Table 5 ). The adjusted odds ratio for bowel obstruction was 0.93 (95% CI: 0.88 to 0.98, p ¼ .0041). The adjusted odds ratio for nausea and vomiting was 0.79 (95% CI: 0.73 to 0.86, p < .0001). The adjusted odds ratio for respiratory depression was 0.91 (95% CI: 0.85 to 0.96, p ¼ .0011).
Hospital readmission and discharge
IV APAP recipients were associated with a lower risk of readmission, with an odds ratio of 0.78 (95% CI: 0.65 to 0.91, p < .0001) in unadjusted analyses (Table 2) , but this was attenuated and no longer statistically significant in multivariable regression at an odds ratio of 0.87 (95% CI: 0.73 to 1.03) ( Table 4 ). The unadjusted rate of discharge to skilled nursing was 48% lower (odds ratio: 0.52, 95% CI: 0.50 to 0.54, p < .0001) ( Table 3 ). This association held in the multivariable logistic regression for discharge to skilled nursing with an odds ratio of 0.66 for the IV APAP recipients (95% CI: 0.63 to 0.69, p < .0001) ( Table 5 ).
Discussion
We found that spine surgery patients whose postoperative pain management included IV APAP were associated with shorter LOS, lower hospitalization costs, lower opioid doses, less complications, and lower rates of discharge to skilled nursing facilities compared to similar patients who were instead using oral APAP. The reduction in LOS of more than half a day and associated cost savings of over $1000 are meaningful differences for hospitals in terms of efficiency and the opportunity to serve more patients. Coupling this with an important decrease in opioid dose of over 10 mg MED per day is associated with meaningful and tangible outcomes for patients in terms of reduced rates of bowel obstruction (including ileus), nausea and vomiting, respiratory depression, and discharge to skilled nursing facilities. This represents a constellation of improved outcomes that benefit both patients and the hospitals caring for them. There are also real financial implications of the reduction in discharges to skilled nursing facilities that are not included in our estimate of hospitalization costs. However, we can estimate the financial impact of the potentially avoided discharges to skilled nursing facilities using the odds ratio estimate. If we assume that those discharges incurred the median national cost of one week stay in a shared room ($6692/month divided by four 14 ), the estimated cost savings resulting from using IV APAP in those who received oral APAP (34% relative reduction to 7.8% or 4747, a difference of 2446 discharges to skilled nursing) in our study is projected to be in excess of $4 million dollars ($6692/4 Â 2446).
These findings are consistent with prior research in other surgical procedures, but to our knowledge represent the first real world study directly estimating the difference in effectiveness between IV and oral APAP. These findings also align with biological evidence of the potential interaction between morphine and oral APAP due to the inhibition of gastrointestinal motility by opioids, leading oral APAP to provide inadequate pain control in the surgical setting 15 . From the perspective of treatment protocol and medical policy development, this real world evidence is critical to help inform providers and hospital administrators about the benefits of IV APAP as part of multimodal analgesia 5, 6, [16] [17] [18] . The body of literature regarding the use of IV APAP for postoperative pain consistently finds associations supporting the use of IV APAP to improve patient outcomes and reduce hospitalization costs 5, [16] [17] [18] .
Limitations
This study has several limitations that should be considered when evaluating the results presented above. The populations compared in each cohort were not randomly assigned and, although we applied techniques to attempt to control for selection bias, other unmeasured confounding of the association may still be present. One such source of confounding could be differences in regional anesthesia techniques or other analgesic medications that were used in the two cohorts. Our analyses did not control for the use of regional anesthesia and we acknowledge that, while it is uncommon, this may bias our findings. It is possible that differential use of another analgesic between the two groups could exacerbate or reduce the signals we observed. However, with the exception of the difference in choice of oral hydrocodone versus oral oxycodone between the two groups, this seems unlikely. Second, we were only able to observe readmission to the same hospital and thus the estimates of 30-day readmission may be biased. However, we have no reason to believe that this bias would be different between the IV and oral APAP groups, thus the estimated relative difference is unlikely to be impacted by this. Third, there are different types of spine surgeries and it is possible that within subgroups of surgeries there are different outcomes. We undertook a post-hoc subgroup analysis by adjusting for surgery type (discectomy, fracture, fusion, and laminectomy) in our multivariable regressions. Small changes in the effects were noted but the magnitude and statistical significance of the overall differences in all outcomes was unchanged.
Like all observational data sources, the Premier Database has a few unique limitations. The information related to administered medications is based on charges. As such, the actual dose of medications administered was not available. While it is accepted that utilization of opioids is likely lower than recorded based on Premier hospital audits, we do not expect any systematic differences between patients who receive IV versus oral APAP and thus the difference between our two groups of interest is expected to be a valid estimate. Although the database consists of an approximately 20% sample of hospitals in the US, they are not randomly sampled and some populations are likely under-represented. However, based on the large sample sizes in each cohort, we believe that this study represents the largest possible inpatient sample that spans both the private and publicly insured (Medicaid and Medicare) populations.
Conclusion
Compared to oral APAP, managing post-spine-surgery pain with IV APAP is associated with shorter LOS, decreased total hospitalization costs, lower doses of opioids, reduced risk of complications, and reduced risk of discharge to a skilled nursing facility. With the potential to assist in enhancing recovery and producing more cost-effective care than oral APAP, clinicians and hospital administrators managing the postoperative care of spine surgery patients should consider IV APAP in their multimodal pain management regimen as a means of targeting the IHI Triple Aim.
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